A common problem arising in the treatment course of patients with IBD is non-adherence to anti-TNF agents, which is estimated to be from 17% to 45% and is associated with an increase in healthcare utilization and health services cost [126,127,128]. The gene discussed is TNF; the disease is irritable bowel syndrome.